Search Results for: Prima terapia farmacologica per l’apnea notturna (OSAS)

Dalla fine della terapia non ha presentato segni clinici

Fda, il via libera per un sarcoma sinoviale è una pietra miliare

Tecnologia dell’Università Carlo Bo esplora uso di globuli rossi

People with moderate to severe obstructive sleep apnea who received tirzepatide, marketed as Zepbound, for 52 weeks cut the number of times per night that they stopped breathing or weren’t getting enough oxygen by about half compared with those who received a placebo, according to a pair of randomized clinical trials involving 469 total participants with obesity.

Studio su terapia non invasiva, sufficiente seduta di 40 minuti

Studio identifica i pazienti a rischio di chirurgia inefficace

In Reply We thank Dr Montalva and colleagues for their comments regarding apnea occurrence and anesthetic approach for inguinal hernia repair in response to our multicenter randomized clinical trial examining the timing of hernia repair in preterm infants. We enrolled smaller and more immature infants than most available studies, including the General Anesthesia compared to Spinal anesthesia (GAS) study. The surgical and anesthetic methods were used at the discretion of the clinicians and the finding that 99% of the cases received general anesthesia is consistent with current practice for the trial population at the 39 participating sites.

A new study published in JAMA Otolaryngology–Head & Neck Surgery may provide guidance for people who snore but don’t have obstructive sleep apnea—and their partners.